Gujarat Themis Biosyn: Credit Rating Downgraded by CARE Ratings
Gujarat Themis Biosyn's credit ratings were downgraded by CARE Ratings. Long-term facilities (₹77.39 crore) moved to CARE BB+; Stable from CARE BBB-; Negative, and short-term facilities (₹48.50 crore) to CARE A4+ from CARE A3. This reflects a decline in profitability and operational scale.
A downgrade in credit ratings can affect the company's borrowing costs, access to credit, and investor confidence, thus having a medium-term impact on its operations and financial strategy.
The credit rating has been downgraded, indicating a negative outlook on the company's financial health and ability to meet its obligations.
Gujarat Themis Biosyn Limited (GUJTHEM), operating under Themis Medicare Limited (TML), has had its credit ratings for bank facilities reviewed and downgraded by CARE Ratings Limited. The long-term bank facilities, amounting to ₹77.39 crore, have been downgraded from CARE BBB-; Negative to CARE BB+; Stable. The short-term bank facilities, totaling ₹48.50 crore, have been downgraded from CARE A3 to CARE A4+.
The downgrade is attributed to a significant deterioration in profitability margins in FY26 and Q1FY27, driven by increased competition for high-margin products and reduced prices in the API segment. The company reported a PBILDT loss of ₹51.43 crore in Q1FY27 due to substantial debtors and revenue write-offs. While the sale of a part of its investments in Gujarat Themis Biosyn Limited (GTBL) provided liquidity of ₹100 crore in Q1FY27, promoter share pledge increased to fund this purchase. CARE Ratings expects profitability to remain subdued due to product mix and competition, though the funds raised are expected to support near-term liquidity. The ratings are constrained by moderate operations, weak debt coverage indicators, and working capital intensity, but derive strength from experienced management and accredited facilities.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.